Macquarie Group’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-400,000
| Closed | -$269K | – | 1387 |
|
|
2025
Q3 | $269K | Hold |
400,000
| – | – | ﹤0.01% | 1466 |
|
|
2025
Q2 | $217K | Hold |
400,000
| – | – | ﹤0.01% | 1532 |
|
|
2025
Q1 | $262K | Hold |
400,000
| – | – | ﹤0.01% | 1525 |
|
|
2024
Q4 | $408K | Hold |
400,000
| – | – | ﹤0.01% | 1462 |
|
|
2024
Q3 | $346K | Sell |
400,000
-7,669
| -2% | -$5.62K | ﹤0.01% | 1515 |
|
|
2024
Q2 | $146K | Buy |
407,669
+7,669
| +2% | +$4.14K | ﹤0.01% | 1572 |
|
|
2024
Q1 | $268K | Hold |
400,000
| – | – | ﹤0.01% | 1501 |
|
|
2023
Q4 | $217K | Hold |
400,000
| – | – | ﹤0.01% | 1543 |
|
|
2023
Q3 | $240K | Hold |
400,000
| – | – | ﹤0.01% | 1509 |
|
|
2023
Q2 | $520K | Hold |
400,000
| – | – | ﹤0.01% | 1455 |
|
|
2023
Q1 | $704K | Hold |
400,000
| – | – | ﹤0.01% | 1424 |
|
|
2022
Q4 | $1.26M | Sell |
400,000
-260
| -0.1% | -$1.01K | ﹤0.01% | 1357 |
|
|
2022
Q3 | $1.97M | Sell |
400,260
-1,875
| -0.5% | -$9.63K | ﹤0.01% | 1234 |
|
|
2022
Q2 | $1.67M | Hold |
402,135
| – | – | ﹤0.01% | 1356 |
|
|
2022
Q1 | $2.34K | Hold |
402,135
| – | – | ﹤0.01% | 1326 |
|
|
2021
Q4 | $3.02M | Hold |
402,135
| – | – | ﹤0.01% | 1258 |
|
|
2021
Q3 | $3.62M | Hold |
402,135
| – | – | ﹤0.01% | 1197 |
|
|
2021
Q2 | $4.81M | Sell |
402,135
-976
| -0.2% | -$11.1K | ﹤0.01% | 1140 |
|
|
2021
Q1 | $5.05M | Buy |
403,111
+1,830
| +0.5% | +$24.7K | 0.01% | 905 |
|
|
2020
Q4 | $6.26M | Hold |
401,281
| – | – | 0.01% | 829 |
|
|
2020
Q3 | $3.79M | Sell |
401,281
-3,237
| -0.8% | -$35K | 0.01% | 890 |
|
|
2020
Q2 | $3.62M | Buy |
404,518
+4,518
| +1% | +$41.9K | 0.01% | 860 |
|
|
2020
Q1 | $2.55M | Hold |
400,000
| – | – | 0.01% | 863 |
|
|
2019
Q4 | $3.35M | Hold |
400,000
| – | – | ﹤0.01% | 901 |
|
|
2019
Q3 | $3.62M | Hold |
400,000
| – | – | 0.01% | 842 |
|
|
2019
Q2 | $4.31M | Buy |
400,000
+285,000
| +248% | +$3.03M | 0.01% | 813 |
|
|
2019
Q1 | $1.1M | Buy |
115,000
+61,148
| +114% | +$625K | ﹤0.01% | 1163 |
|
|
2018
Q4 | $618K | Buy |
53,852
+1,400
| +3% | +$17.4K | ﹤0.01% | 1255 |
|
|
2018
Q3 | $889K | Sell |
52,452
-3,310
| -6% | -$50.3K | ﹤0.01% | 1231 |
|
|
2018
Q2 | $792K | Buy |
55,762
+22,196
| +66% | +$369K | ﹤0.01% | 1238 |
|
|
2018
Q1 | $638K | Buy |
33,566
+13,466
| +67% | +$288K | ﹤0.01% | 1310 |
|
|
2017
Q4 | $330K | Buy |
20,100
+18,300
| +1,017% | +$272K | ﹤0.01% | 1574 |
|
|
2017
Q3 | $27K | Buy |
+1,800
| New | +$19.9K | ﹤0.01% | 2068 |
|
Other funds holding SGMO
WA
Macquarie Group's SGMO Position: Q4 2025 in Review
Macquarie Group sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q4 2025, closing a stake of 400,000 shares — an estimated $269K sold.
Macquarie Group first reported a position in SGMO in Q3 2017 and held it in 33 quarters. The position peaked at $6.26M in Q4 2020. 105 funds tracked by Wall St. Rank hold SGMO as of Q4 2025.
- Macquarie Group reported no remaining SANGAMO THERAPEUTICS INC position as of Q4 2025 after selling out during the quarter.
- Macquarie Group sold 400,000 SANGAMO THERAPEUTICS INC shares in Q4 2025, an estimated $269K.
- Macquarie Group first reported a position in SANGAMO THERAPEUTICS INC in Q3 2017 and held it in 33 quarters.
- Macquarie Group's SANGAMO THERAPEUTICS INC position peaked at $6.26M in Q4 2020.
- 105 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q4 2025.
Based on Macquarie Group's 13F filing for Q4 2025, filed 13 Feb 2026.